Quick Answer
Enliven Therapeutics, Inc. reported Net Income of -$103.69 million for fiscal year 2025.
Enliven Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$103.69M -16.5% |
-$89.02M -24.4% |
-$71.58M -90.1% |
-$37.66M +26.7% |
-$51.38M -24.2% |
-$41.36M -76.3% |
| Diluted EPS | -$1.83 +3.2% |
-$1.89 +6.0% |
-$2.01 +83.3% |
-$12.05 -408.4% |
-$2.37 | — |
| Total Assets | $476.17M +46.2% |
$325.76M +19.8% |
$271.87M +226.4% |
$83.30M -11.1% |
$93.65M +3.1% |
$90.84M +172.8% |
| Cash and Equivalents | $98.90M -20.3% |
$124.12M +23.9% |
$100.14M +32.6% |
$75.54M +56.4% |
$48.31M +1.3% |
$47.70M +866.3% |
| Stockholders Equity | $459.60M +48.3% |
$309.85M +26.0% |
$245.91M +420.1% |
-$76.83M -79.1% |
-$42.89M -150.8% |
$84.44M +272.9% |
| R&D Expense | $85.86M +6.3% |
$80.78M +25.1% |
$64.57M +108.2% |
$31.02M -19.3% |
$38.44M +19.6% |
$32.15M +69.2% |
| Operating Income | -$119.66M -14.4% |
-$104.55M -25.2% |
-$83.53M -115.3% |
-$38.79M +24.6% |
-$51.44M -23.4% |
-$41.70M -72.9% |
| Shares Outstanding | 59.44M +21.5% |
48.94M +19.3% |
41.01M +1048.8% |
3.57M -86.4% |
26.29M +49.8% |
17.55M +2397.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$20.15M | +13.0% | +20.5% |
| Diluted EPS | September 30, 2025 | -$0.32 | +33.3% | +34.7% |
| Total Assets | September 30, 2025 | $490.88M | +60.7% | -2.6% |
| Cash and Equivalents | September 30, 2025 | $101.73M | +1.1% | -14.8% |
| Stockholders Equity | September 30, 2025 | $476.12M | +65.1% | -2.5% |
| R&D Expense | September 30, 2025 | $18.23M | -14.3% | -15.2% |
| Operating Income | September 30, 2025 | -$25.10M | +7.3% | +12.2% |
| Shares Outstanding | September 30, 2025 | 59.26M | +25.4% | +0.1% |
- Enliven Therapeutics, Inc. reported Net Income of -$103.69 million for fiscal year 2025.
- Enliven Therapeutics, Inc. showed a decrease of -16.5% in Net Income compared to the prior fiscal year.
- Enliven Therapeutics, Inc. reported Diluted EPS of $1.83 per share (loss) for fiscal year 2025.
- Enliven Therapeutics, Inc. showed an increase of +3.2% in Diluted EPS compared to the prior fiscal year.
- Enliven Therapeutics, Inc. reported Total Assets of $476.17 million for fiscal year 2025.
- Enliven Therapeutics, Inc. showed an increase of +46.2% in Total Assets compared to the prior fiscal year.
- Enliven Therapeutics, Inc. reported Cash and Equivalents of $98.90 million for fiscal year 2025.
- Enliven Therapeutics, Inc. showed a decrease of -20.3% in Cash and Equivalents compared to the prior fiscal year.
- Enliven Therapeutics, Inc. reported Stockholders Equity of $459.60 million for fiscal year 2025.
- Enliven Therapeutics, Inc. showed an increase of +48.3% in Stockholders Equity compared to the prior fiscal year.
- Enliven Therapeutics, Inc. reported R&D Expense of $85.86 million for fiscal year 2025.
- Enliven Therapeutics, Inc. showed an increase of +6.3% in R&D Expense compared to the prior fiscal year.
- Enliven Therapeutics, Inc. reported Operating Income of -$119.66 million for fiscal year 2025.
- Enliven Therapeutics, Inc. showed a decrease of -14.4% in Operating Income compared to the prior fiscal year.
- Enliven Therapeutics, Inc. reported Shares Outstanding of 59.44 million shares for fiscal year 2025.
- Enliven Therapeutics, Inc. showed an increase of +21.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: